13 results about "Antibody formation" patented technology

The present technology includes methods for detecting an anti-drug antibody (ADA) that binds an anti-TNFα antibody (target antibody) in a sample comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form a complex with the affinity antibody and the detection antibody. The technology also includes methods for determining the ADA concentration in a sample and confirming that a sample comprises ADAs. The technology also includes a kit for performing any of the methods of the present technology.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

The present application relates to a kind of based on electrochemiluminescence immunoassay semeglu-tide content detection method, the kit for detecting semeglu-tide and monoclonal antibody pair, it solves the technical problem that the prior art through LC-MS / MS determination semeglu-tide content exists and is complex, detection flux is low, impurity residue, sample loss amount is big and traditional ELISA detection sensitivity is low, it is by the way that one monoclonal antibody reagent AS-MAB01 is coated on electrochemiluminescence microplate, specifically recognizes and combines semeglu-tide in matrix, then another monoclonal antibody AS-MAB02 labeled with ruthenium is added to form sandwich complex, finally, high sensitivity semeglu-tide quantitative detection purpose is achieved by electrochemiluminescence principle.The present application can be used for the quantitative detection of semeglu-tide in mouse, monkey and human-derived serum samples.

The embodiment of the invention provides a PLGF and sFlt-1 double-marker joint detection kit and application. The kit comprises an sFlt-1 labeled antibody, a PlGF labeled antibody, an antibody coated fluorescent magnetic bead working solution, an antibody calibrator, a sample diluent, a cleaning solution, an enzyme solution and an enzyme substrate solution. According to the application, specific capture antibodies of sFlt-1 and PlGF are respectively coupled to different fluorescence coded magnetic beads, so that the specific capture antibodies, an antigen and a detection antibody form a double-antibody sandwich structure, and the double-antibody sandwich structure is cleaned, uniformly mixed and synchronously imaged, so that synchronous and simultaneous testing of sFlt-1 and PlGF in the same sample is realized, and high-resolution quantitative analysis is carried out. Therefore, the application of the joint detection kit significantly simplifies the detection process, reduces the cost, improves the detection flux and efficiency, effectively improves the sensitivity and accuracy of preeclampsia risk assessment, and has important clinical popularization value.

The invention discloses a kappa light chain detection kit and a preparation method, and relates to the technical field of clinical in-vitro detection reagents, the kit is in a double-reagent form, the double reagents comprise a reagent R1 and a reagent R2, the reagent R2 comprises a capture antibody and a detection antibody which can be specifically combined with different epitopes of a kappa light chain, and the detection antibody comprises a reagent R1 and a reagent R2 which can be specifically combined with different epitopes of the kappa light chain. A capture antibody-antigen-detection antibody sandwich structure is formed to improve the hook effect in detection. The kappa light chain detection reagent provided by the invention solves the problems that the existing kappa light chain detection reagent mostly uses a single antibody and a hook effect is easy to occur due to reduction of a HOOK point, a capture antibody-antigen-detection antibody sandwich structure is formed by two antibodies (capture antibody and detection antibody) aiming at different epitopes of an antigen, and the core is a specific binding mode, so that the recognition precision of the antigen can be improved, and the detection accuracy of the kappa light chain detection reagent is improved. And non-specific binding is reduced, the detection sensitivity and HOOK point are greatly improved, and further popularization and application in the market are facilitated.

The invention aims at providing an acute gouty arthritis diagnosis and treatment preparation based on natural antioxidants and a preparation method and application thereof, and belongs to the technical field of nano biomedical materials.The acute gouty arthritis diagnosis and treatment preparation is self-assembled with spheroidic tea polyphenol and acidified rutin as sources and comprises a polyphenol hydroxyl structure of the natural antioxidants, and the natural antioxidants are added into the polyphenol hydroxyl structure of the natural antioxidants; the nano-probe is formed by coating maleoyl bovine serum albumin (MBSA) and then coupling a NOX2 antibody through an antibody drug coupling technology, and the nano-probe with integrated diagnosis and treatment of acute gouty arthritis is constructed. The nano probe can be used for positioning an acute gouty arthritis part in real time under the guidance of near-infrared region imaging; the probe can directionally remove macrophages and microenvironment high-expression reactive oxygen species (ROS), and the preparation method of the probe is simple and easy to implement.

The invention discloses a novel immunodetection method and application. The immunodetection method comprises the following steps: coating a captured antibody and a single-site recognition antigen on a solid-phase carrier; adding a to-be-detected sample and a biotin-labeled mixed detection antibody for incubation, so that the target antigen forms a double-antibody sandwich compound, and the single-site recognition antigen and the detection antibody form a competitive compound; after streptavidin marked by chemiluminescence is added for incubation, signal values of the two compounds are detected; whether interference exists or not is judged and detected by comparing the double signals, and the content of the target antigen is determined. The immunodetection method can effectively identify cross interference and hook effect, and improves the accuracy and reliability of multi-index detection.

The present technology includes a method for detecting anti-drug antibodies (ADAs) that bind to anti-TNF [alpha] antibodies (target antibodies) in a sample, the method comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form complexes with the affinity antibody and the detection antibody. The techniques also include methods for determining the concentration of ADA in a sample and confirming that the sample contains ADA. The technology also includes a kit for performing any of the methods of the technology.

This invention relates to a protein detection method. Specifically, the method introduces magnetic beads to capture antibodies that bind to the target protein structure, forming a triple-antibody sandwich protein-magnetic bead complex. This complex is then detected to obtain the target protein detection result. The method of this invention exhibits good stability, high sensitivity, high efficiency, low background signal, and simple operation steps.

The present invention provides a composition comprising the following thyroid stimulating hormone receptor (TSHR) peptides: (i) all or a portion of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 1; and (ii) all or a portion of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 2. The invention also relates to the use of such compositions in the prevention or inhibition of activated autoantibody formation in Graves's disease.

The invention belongs to the technical field of biology, and particularly discloses an anti-aeromonas cainea egg yolk antibody as well as a preparation method and application thereof. The invention relates to an anti-aeromonas cainea egg yolk antibody, which is prepared by immunizing laying hens by using an inactivated vaccine prepared from aeromonas cainea RDBAE-24091, collecting hyper-immune eggs, and separating and purifying the hyper-immune eggs to obtain the anti-aeromonas cainea egg yolk antibody. The method comprises the following steps: carrying out inactivation treatment on aeromonas caviridis RDBAE-24091 to prepare an inactivated vaccine, inoculating the vaccine into a laying hen body, inducing the laying hen to generate a specific immune reaction, enabling an immune system of the laying hen to generate an antibody aiming at the aeromonas caviridis to form a hyper-immune egg, carrying out separation and purification on the hyper-immune egg, removing impurities in egg liquid, and carrying out purification on the hyper-immune egg so as to obtain the laying hen feed. A high-purity and high-activity target product is obtained, and an egg yolk antibody product which aims at the aeromonas cainea and has both green safety and targeted antibacterial efficiency is provided.

The invention discloses an antibody combined with an E2-E2 antibody compound, and relates to the field of antibodies. The antibody combined with the E2-E2 antibody compound comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody is strongly combined with the E2 and the compound formed by the E2 antibody, is not combined with the free E2 antibody or is not combined with the free E2, the antibody provides an important raw material source for the detection of the E2, and the detection cost is reduced. And the antibody has good sensitivity and activity, good detection linear relationship and relatively high clinical correlation.

The present application relates to a series of 2'-deoxy-2',2'-difluoro cytidine (2',2'-difluoro 2'-deoxycytidine, dFdC, gemcitabine) Protide and antibody specific to tumor antigen form conjugates and its preparation method and application in the field of treatment. Further, the present application provides a series of antibody-linker-2'-deoxy-2',2'-difluoro cytidine Protide conjugate to form antibody drug conjugate (ADC). The structural features are mainly in the 5'-phosphate phenylamide amino acid ester corresponding group in the structure of 2'-deoxy-2',2'-difluoro cytidine and the linker for linkage, and then coupled with the corresponding tumor specific antibody to form ADC. These ADCs target antigens on tumor cells, endocytose into tumor cells, release the drug 2'-deoxy-2',2'-difluoro cytidine monophosphate, kill tumor cells, and cause tumor cell apoptosis.